• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

制药行业临床前 QSP 模型：一项考察当前现状的 IQ 联盟调查。

Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape.

机构信息

Abbvie Inc, North Chicago, Illinois, USA.

Novartis Institutes for Biomedical Research, East Hanover, New Jersey, USA.

出版信息

CPT Pharmacometrics Syst Pharmacol. 2018 Mar;7(3):135-146. doi: 10.1002/psp4.12282. Epub 2018 Feb 1.

DOI:10.1002/psp4.12282
PMID:29349875
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5869550/
Abstract

A cross-industry survey was conducted to assess the landscape of preclinical quantitative systems pharmacology (QSP) modeling within pharmaceutical companies. This article presents the survey results, which provide insights on the current state of preclinical QSP modeling in addition to future opportunities. Our results call attention to the need for an aligned definition and consistent terminology around QSP, yet highlight the broad applicability and benefits preclinical QSP modeling is currently delivering.

摘要

进行了一项跨行业调查，以评估制药公司内临床前定量系统药理学 (QSP) 建模的现状。本文介绍了调查结果，除了未来的机会外，这些结果还提供了对临床前 QSP 建模现状的深入了解。我们的结果表明需要对 QSP 进行一致的定义和术语，但同时也强调了临床前 QSP 建模的广泛适用性和目前带来的益处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf5f/5869550/b75c3cc086bf/PSP4-7-135-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf5f/5869550/813a15f48662/PSP4-7-135-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf5f/5869550/7fcb02a51409/PSP4-7-135-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf5f/5869550/cf969f173a3b/PSP4-7-135-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf5f/5869550/3772841b4ba4/PSP4-7-135-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf5f/5869550/2ef9928cb56b/PSP4-7-135-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf5f/5869550/a4d8a60d8e7d/PSP4-7-135-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf5f/5869550/0e1fccc2bbae/PSP4-7-135-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf5f/5869550/b75c3cc086bf/PSP4-7-135-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf5f/5869550/813a15f48662/PSP4-7-135-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf5f/5869550/7fcb02a51409/PSP4-7-135-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf5f/5869550/cf969f173a3b/PSP4-7-135-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf5f/5869550/3772841b4ba4/PSP4-7-135-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf5f/5869550/2ef9928cb56b/PSP4-7-135-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf5f/5869550/a4d8a60d8e7d/PSP4-7-135-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf5f/5869550/0e1fccc2bbae/PSP4-7-135-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf5f/5869550/b75c3cc086bf/PSP4-7-135-g008.jpg

相似文献

1
Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape.制药行业临床前 QSP 模型：一项考察当前现状的 IQ 联盟调查。
CPT Pharmacometrics Syst Pharmacol. 2018 Mar;7(3):135-146. doi: 10.1002/psp4.12282. Epub 2018 Feb 1.
2
Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.制药行业的临床前药代动力学/药效学建模与模拟：IQ联盟对当前现状的调查
AAPS J. 2015 Mar;17(2):462-73. doi: 10.1208/s12248-014-9716-2. Epub 2015 Jan 29.
3
Current practices for QSP model assessment: an IQ consortium survey.当前定量构效关系模型评价实践：IQ 联盟调查。
J Pharmacokinet Pharmacodyn. 2024 Oct;51(5):543-555. doi: 10.1007/s10928-022-09811-1. Epub 2022 Aug 11.
4
Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.医药行业的转化药代动力学-药效学分析：来自 IQ 联盟 PK-PD 讨论小组的观点。
Drug Discov Today. 2017 Oct;22(10):1447-1459. doi: 10.1016/j.drudis.2017.04.015. Epub 2017 May 2.
5
In vitro secondary pharmacological profiling: An IQ-DruSafe industry survey on current practices.体外二级药理学分析：IQ-DruSafe行业当前实践调查
J Pharmacol Toxicol Methods. 2018 Sep-Oct;93:7-14. doi: 10.1016/j.vascn.2018.07.001. Epub 2018 Jul 17.
6
[An introduction to QSP modeling for pharmacologists].面向药理学家的定量系统药理学建模导论
Nihon Yakurigaku Zasshi. 2019;154(3):143-150. doi: 10.1254/fpj.154.143.
7
Quantitative Systems Pharmacology: A Case for Disease Models.定量系统药理学：疾病模型的一个实例
Clin Pharmacol Ther. 2017 Jan;101(1):24-27. doi: 10.1002/cpt.528. Epub 2016 Nov 18.
8
Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development.整合而非孤立：为药物发现和开发中的定量和系统药理学辩护。
Drug Discov Today. 2011 Dec;16(23-24):1031-6. doi: 10.1016/j.drudis.2011.10.001. Epub 2011 Oct 13.
9
Benefits and challenges of a QSP approach through case study: Evaluation of a hypothetical GLP-1/GIP dual agonist therapy.通过案例研究探讨定量系统药理学（QSP）方法的益处与挑战：对一种假设的胰高血糖素样肽-1/葡萄糖依赖性促胰岛素多肽（GLP-1/GIP）双重激动剂疗法的评估
Eur J Pharm Sci. 2016 Oct 30;94:15-19. doi: 10.1016/j.ejps.2016.05.006. Epub 2016 May 6.
10
Integrating pharmacology and clinical pharmacology in pharmaceutical companies.制药公司中整合药理学与临床药理学
Br J Clin Pharmacol. 2012 Jun;73(6):927-30. doi: 10.1111/j.1365-2125.2012.04239.x.

引用本文的文献

1
Virtual patients inspired by multiomics predict the efficacy of an anti-IFNα mAb in cutaneous lupus.受多组学启发的虚拟患者预测抗IFNα单克隆抗体在皮肤性狼疮中的疗效。
iScience. 2025 Jan 6;28(2):111754. doi: 10.1016/j.isci.2025.111754. eCollection 2025 Feb 21.
2
Quantitative systems toxicology modeling in pharmaceutical research and development: An industry-wide survey and selected case study examples.药物研发中的定量系统毒理学建模：全行业调查及部分案例研究示例
CPT Pharmacometrics Syst Pharmacol. 2024 Dec;13(12):2036-2051. doi: 10.1002/psp4.13227. Epub 2024 Oct 16.
3
Applying quantitative and systems pharmacology to drug development and beyond: An introduction to clinical pharmacologists.

本文引用的文献

1
Understanding Physiology in the Continuum: Integration of Information from Multiple - Levels.理解连续统一体中的生理学：整合多层次信息。
Front Pharmacol. 2017 Feb 27;8:91. doi: 10.3389/fphar.2017.00091. eCollection 2017.
2
Trends in clinical success rates.临床成功率的趋势。
Nat Rev Drug Discov. 2016 Jun;15(6):379-80. doi: 10.1038/nrd.2016.85. Epub 2016 May 20.
3
Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.模型引导的药物发现与开发中的良好实践：实践、应用与文档记录
应用定量和系统药理学进行药物研发及其他领域：临床药理学家简介。
Indian J Pharmacol. 2024 Jul 1;56(4):268-276. doi: 10.4103/ijp.ijp_644_23. Epub 2024 Sep 10.
4
Life scientists improve QSP model quality and impact.生命科学家提高了定量系统药理学（QSP）模型的质量和影响力。
Front Pharmacol. 2024 Jul 2;15:1392747. doi: 10.3389/fphar.2024.1392747. eCollection 2024.
5
Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice.运用机制数学建模推进癌症药物研发：弥合理论与实践之间的差距。
J Pharmacokinet Pharmacodyn. 2024 Dec;51(6):581-604. doi: 10.1007/s10928-024-09930-x. Epub 2024 Jun 21.
6
Leveraging multi-omics data to empower quantitative systems pharmacology in immuno-oncology.利用多组学数据增强免疫肿瘤学中的定量系统药理学。
Brief Bioinform. 2024 Mar 27;25(3). doi: 10.1093/bib/bbae131.
7
Mathematical modeling in autoimmune diseases: from theory to clinical application.自身免疫性疾病的数学建模：从理论到临床应用。
Front Immunol. 2024 Mar 14;15:1371620. doi: 10.3389/fimmu.2024.1371620. eCollection 2024.
8
Digital patient twins for personalized therapeutics and pharmaceutical manufacturing.用于个性化治疗和药物制造的数字患者替身
Front Digit Health. 2024 Jan 5;5:1302338. doi: 10.3389/fdgth.2023.1302338. eCollection 2023.
9
Glycolysis in Chronic Liver Diseases: Mechanistic Insights and Therapeutic Opportunities.慢性肝脏疾病中的糖酵解：机制见解与治疗机遇。
Cells. 2023 Jul 26;12(15):1930. doi: 10.3390/cells12151930.
10
A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody Programs.一种作用机制位点模型：一种用于为治疗性拮抗抗体项目确定正确靶点、正确化合物和正确剂量提供信息的工具。
Front Bioinform. 2021 Sep 3;1:731340. doi: 10.3389/fbinf.2021.731340. eCollection 2021.
CPT Pharmacometrics Syst Pharmacol. 2016 Mar;5(3):93-122. doi: 10.1002/psp4.12049. Epub 2016 Mar 14.
4
Innovation in the pharmaceutical industry: New estimates of R&D costs.制药行业的创新：研发成本的新估计
J Health Econ. 2016 May;47:20-33. doi: 10.1016/j.jhealeco.2016.01.012. Epub 2016 Feb 12.
5
Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities.肿瘤学中的免疫疗法及新型联合疗法：当前态势、挑战与机遇
Clin Transl Sci. 2016 Apr;9(2):89-104. doi: 10.1111/cts.12391. Epub 2016 Mar 30.
6
Network-based discovery through mechanistic systems biology. Implications for applications--SMEs and drug discovery: where the action is.基于网络的发现：通过机制性系统生物学。对应用的启示——中小企业与药物发现：行动所在之处。
Drug Discov Today Technol. 2015 Aug;15:41-8. doi: 10.1016/j.ddtec.2015.07.003. Epub 2015 Sep 10.
7
FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment?美国食品药品监督管理局咨询会议临床药理学审查采用定量系统药理学（QSP）模型：一个分水岭时刻？
CPT Pharmacometrics Syst Pharmacol. 2015 Mar;4(3):e00020. doi: 10.1002/psp4.20. Epub 2015 Mar 12.
8
Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.制药行业的临床前药代动力学/药效学建模与模拟：IQ联盟对当前现状的调查
AAPS J. 2015 Mar;17(2):462-73. doi: 10.1208/s12248-014-9716-2. Epub 2015 Jan 29.
9
Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development.定量系统药理学可以降低药物研发的淘汰率并提高生产力。
Front Pharmacol. 2014 Nov 10;5:247. doi: 10.3389/fphar.2014.00247. eCollection 2014.
10
Implementation of quantitative and systems pharmacology in large pharma.大型制药公司中定量与系统药理学的实施。
CPT Pharmacometrics Syst Pharmacol. 2014 Oct 22;3(10):e142. doi: 10.1038/psp.2014.40.